Skip to content

Frontlight ResearchEarly access

Trial site

New Horizon Research Center

Miami, Florida 33165, United StatesNot linked to an institution yet

18running trials
23closed trials

The trials here

What the 41 trials at this site are about, from their registry records.

Conditions: Obesity23 trials
Type 2 diabetes22 trials
Alzheimer disease3 trials
Osteoarthritis3 trials
Diabetic neuropathy2 trials
Alopecia areata1 trial
Obstructive sleep apnoea1 trial
Rheumatoid arthritis1 trial
Type 1 diabetes1 trial
Vitiligo1 trial
Phase: Phase 325 trials
Phase 214 trials
Phase 11 trial
Phase 41 trial
Status: Completed20 trials
Active, not recruiting8 trials
Recruiting7 trials
Not yet recruiting3 trials
Terminated2 trials
Withdrawn1 trial
Lead sponsor: Eli Lilly and Company22 trials
Novo Nordisk A/S9 trials
Amgen5 trials
Pfizer3 trials
Cassava Sciences, Inc.2 trials

Running trials

Not yet recruiting
AMBITION 3: A Research Study Investigating How Well Zenagamtide at Higher Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide in People With Type 2 Diabetes Treated With Metformin, SGLT2i, or Both
NCT07931573· Phase 3· Novo Nordisk A/S· Source
Contact: Novo Nordisk
Not yet recruiting
A Research Study Investigating How Well Zenagamtide at Lower Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide at Lower Dose Levels in People With Type 2 Diabetes Treated With Metformin, Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i), or Both
NCT07931599· Phase 3· Novo Nordisk A/S· Source
Contact: Novo Nordisk
Not yet recruiting
A Study to Investigate the Effect of LY4086940 Versus Placebo in Participants With Obesity or Overweight and Without Type 2 Diabetes
NCT07890376· Phase 2· Eli Lilly and Company· Source
Contact: Lazaro Nunez (principal investigator)
Recruiting
A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Osteoarthritis Pain
NCT07641517· Phase 2· Eli Lilly and Company· Source
Contact: Lazaro Nunez (principal investigator)
Recruiting
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
NCT07564414· Phase 3· Novo Nordisk A/S· Source
Contact: Novo Nordisk
Recruiting
A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
NCT07589608· Phase 2· Eli Lilly and Company· Source
Contact: Lazaro Nunez (principal investigator)
Active, not recruiting
A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity
NCT07575932· Phase 2· Pfizer· Source
Recruiting
Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
NCT07575399· Phase 3· Amgen· Source
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
NCT07392190· Phase 3· Eli Lilly and Company· Source
Contact: Lazaro Nunez (principal investigator)
Active, not recruiting
A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight
NCT07357415· Phase 3· Eli Lilly and Company· Source
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
NCT07282600· Phase 3· Eli Lilly and Company· Source
Contact: Lazaro Nunez (principal investigator)
Active, not recruiting
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
NCT07037433· Phase 3· Amgen· Source
Active, not recruiting
Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
NCT06858878· Phase 3· Amgen· Source
Active, not recruiting
A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM)
NCT06660173· Phase 2· Amgen· Source
Recruiting
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
NCT06143956· Phase 2· Eli Lilly and Company· Source
Contact: Lazaro Nunez (principal investigator)
Active, not recruiting
A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2
NCT06072183· Phase 3· Pfizer· Source
Active, not recruiting
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
NCT04437511· Phase 3· Eli Lilly and Company· Source
Recruiting
A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain
NCT05986292· Phase 2· Eli Lilly and Company· Source
Contact: Lazaro Nunez (principal investigator)

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Closed trials

Withdrawn
A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes
NCT07357740· Phase 2· Novo Nordisk A/S· Source
Terminated
A Study of LY3549492 in Adults With Obesity or Overweight With Type 2 Diabetes
NCT07030868· Phase 2· Eli Lilly and Company· Source
Completed
A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy
NCT06797869· Phase 2· Novo Nordisk A/S· Source
Completed
A Study to Learn About the Study Medicine Called PF-07976016 in Adults With Obesity
NCT06717425· Phase 2· Pfizer· Source
Completed
A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight
NCT06683508· Phase 2· Eli Lilly and Company· Source
Completed
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both
NCT06534411· Phase 3· Novo Nordisk A/S· Source
Completed
A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes
NCT06603571· Phase 2· Eli Lilly and Company· Source
Completed
A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN)
NCT06584916· Phase 3· Eli Lilly and Company· Source
Completed
Single and Multiple Ascending Dose Study of AMG 513 in Participants With Obesity
NCT06585462· Phase 1· Amgen· Source
Completed
Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)
NCT06354660· Phase 3· Eli Lilly and Company· Source
Completed
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
NCT06221969· Phase 3· Novo Nordisk A/S· Source
Completed
A Study of LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain
NCT06074562· Phase 2· Eli Lilly and Company· Source
Completed
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
NCT06065540· Phase 3· Novo Nordisk A/S· Source
Completed
A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
NCT06047548· Phase 3· Eli Lilly and Company· Source
Completed
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight
NCT05929066· Phase 3· Eli Lilly and Company· Source
Completed
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities
NCT05822830· Phase 3· Eli Lilly and Company· Source
Terminated
Open-label Extension for Phase 3 Clinical Trials of Simufilam
NCT05575076· Phase 3· Cassava Sciences, Inc.· Source
Completed
A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)
NCT05514535· Phase 3· Novo Nordisk A/S· Source
Completed
A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin
NCT05275400· Phase 3· Eli Lilly and Company· Source
Completed
Simufilam 100 mg for Mild-to-Moderate Alzheimer's Disease
NCT04994483· Phase 3· Cassava Sciences, Inc.· Source
Completed
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight
NCT04184622· Phase 3· Eli Lilly and Company· Source
Completed
A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata
NCT03899259· Phase 3· Eli Lilly and Company· Source
Completed
A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis
NCT03915964· Phase 4· Eli Lilly and Company· Source

Site data: ClinicalTrials.govUpdated 15 Nov 2026

Report an error

New Horizon Research Center: trial site – Frontlight Research